Chambers Georgina M, Ho Maria T, Sullivan Elizabeth A
School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
Med J Aust. 2006 Feb 20;184(4):155-8. doi: 10.5694/j.1326-5377.2006.tb00174.x.
To calculate the cost of assisted reproductive technology (ART) treatment cycles and resultant live-birth events.
Cost-outcome study based on a decision analysis model of significant clinical and economic outcomes of ART.
All non-donor ART treatments initiated in Australia in 2002. Treatment cycles, maternal age and birth outcome data were obtained from the Australian and New Zealand Assisted Reproduction Database. Direct health care costs were obtained from fertility centres, and included government, private insurer and patient costs.
Average health care cost of non-donor, fresh and frozen embryo ART treatment cycles. Average and age-specific costs per live-birth event following ART treatment.
Average health care cost per non-donor ART live-birth event was 32,903 US dollars (range, 24,809 US dollars for women < 30 years to 97,884 US dollars for women > or = 40 years). The cost per live birth for women aged > or = 42 years was 182,794 US dollars. The average treatment cost of a fresh cycle was 6,940 US dollars, compared with 1,937 US dollars for a frozen embryo transfer cycle.
Debate regarding funding for ART services has been hindered by a lack of economic studies of ART treatments and outcomes in Australia. This is the most comprehensive costing study of ART services to date in terms of resources consumed during ART treatment. It confirms that ART treatment is less cost-effective in older women. Alongside economic considerations of ART, community values, ethical judgements and clinical factors should influence policy decision-making.
计算辅助生殖技术（ART）治疗周期及由此产生的活产事件的成本。
基于ART重大临床和经济结果的决策分析模型的成本效益研究。
2002年在澳大利亚启动的所有非供体ART治疗。治疗周期、产妇年龄和出生结局数据来自澳大利亚和新西兰辅助生殖数据库。直接医疗费用来自生育中心，包括政府、私人保险公司和患者费用。
非供体、新鲜和冷冻胚胎ART治疗周期的平均医疗费用。ART治疗后每例活产事件的平均成本及按年龄划分的成本。
非供体ART活产事件的平均医疗费用为32,903美元（范围为，30岁以下女性为24,809美元，40岁及以上女性为97,884美元）。42岁及以上女性的每例活产成本为182,794美元。新鲜周期的平均治疗成本为6,940美元，而冷冻胚胎移植周期为1,937美元。
在澳大利亚，由于缺乏对ART治疗及其结果的经济研究，有关ART服务资金的辩论受到了阻碍。就ART治疗期间消耗的资源而言，这是迄今为止最全面的ART服务成本核算研究。它证实了ART治疗在老年女性中成本效益较低。除了ART的经济考量外，社区价值观、伦理判断和临床因素也应影响政策决策。
